Pharma among top-paid Indian execs; Teva gets FDA nod for one-dose Plan B;

> Pharma execs are among the highest paid in India, with three of the seven highest-paid executives hailing from Ranbaxy Laboratories, Dr Reddy's Labs and Piramal Healthcare. Report

> Teva Pharmaceutical industries won FDA approval for a one-dose form of the emergency contraceptive Plan B. Report

> Danish drugmaker Novo Nordisk is facing accusations by Swedish authorities that it treated hospital staff to an all-expenses-paid conference trip to South Africa, which if proven could lead to bribery charges. Report

> Par Pharmaceutical got the tentative FDA nod for its version of once-daily Tramadol, but patent disputes remain between Par, Purdue Pharma and Biovail, which make branded forms of the drug. Report

> Medtronic recalled specific lots of its Paradigm Quick Set infusion sets used with Minimed Paradign insulin pumps because they may not work properly. Report

> Sanofi-Aventis has recalled three cough mixtures for babies and children in France after traces of a toxic substance were discovered in a bottle, the French health authority said. Report

> Elan plans to delist from the London Stock Exchange due to low volumes but retain its primary Dublin listing and a presence on the New York Stock Exchange. Report

And Finally... Omega-3 fatty acid supplements did nothing to slow memory declines in people with mild to moderate Alzheimer's, but a study in healthy people with slight memory complaints did show promise. Report

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Incyte and Novartis' Jakafi is eying a nod in chronic graft vs. host disease—and it may just have the data to get it done.

With a slate of vaccine authorizations on the horizon, vaccine execs from a trio of leading shot makers are looking at distribution hurdles ahead.

News of an FDA plant inspection for a Macrogenics drug boosted investor confidence in BMS' ability to meet its year-end deadline for liso-cel.